Medley Therapeutics (formerly YAP Therapeutics) pioneers the development of advanced biologics and genetic medicines to treat chronic and life-threatening diseases. Founded with a vision to regenerate heart tissue, the company’s portfolio includes genetic medicines to endogenously regenerate organs and treat cardiac arrhythmias, as well as advanced biologics targeting oncology and fibrotic diseases. Medley’s lead gene therapy candidate, YAP101, is designed to drive cardiac regeneration through modulation of the Hippo/YAP signaling pathway and related mechanisms.

Medley Therapeutics

Org chart

Teams

Offices